Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Hepatocellular 3Breast Neoplasms 3Sarcoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinoma 1Triple Negative Breast Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Osteosarcoma 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Breast Cancer Organoids 1

Interventions

Carboplatin 5pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × pirarubicin × Clear all
NCT02613026 2015-11-24

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

307 Hospital of PLA

Phase 3 Completed
104 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡